Clinical trial
Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple…
NCT00116961 · University of Michigan Rogel Cancer Center, Other · Completed
Key facts
| NCT number | NCT00116961 |
|---|---|
| Title | Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma |
| Official title | A Phase II Study of Combination of Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma |
| Lead sponsor | University of Michigan Rogel Cancer Center, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Velcade, Doxil, Dexamethasone |
| Enrollment | 40 |
| Start date | Jun 1, 2005 |
| Primary completion | Jan 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Jul 1, 2005 |
| Last update posted | Feb 7, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: